32 results about "Skeletal disorder" patented technology

The invention belongs to the field of biological products, and particularly relates to a bone glue product for preventing and treating osteoporosis and application, the bone glue comprises sheep bone glue (small molecules), pig bone glue (small molecules) and black pig bone glue (small molecules); five animals are beneficial, sheep and pigs are food beneficial to body health, bones are made into bone glue (small molecules) through modern production processes such as an enzyme preparation method and the like, the bone glue (small molecules) is easily dissolved in water and easily absorbed by a human body, can supplement colloid in the bones, is non-toxic and can be eaten for a long time; due to different yin and yang attributes, different types of osteoporosis patients can be prevented and treated; the traditional Chinese medicine also has good prevention and treatment effects on complications, fracture, hairline fracture, arthralgia and other bone diseases caused by osteoporosis; the compound can be applied to preparation of medicines, foods and health-care foods for preventing and treating osteoporosis.

The present invention relates to a composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.

The application discloses a functional composition for improving bone and joint health, a conditioner and application. The functional composition comprises a first active component and a second active component; the first active component comprises elastin peptide, haematococcus pluvialis and ergothioneine; and the second active component comprises one or more of houttuynia cordata and non-denatured type II collagen. The application realizes the protection effect on joint, cartilage and bone health by scientific matching of the components and synergistically improving the glycosaminoglycan level in chondrocytes and the osteocalcin level in osteoblasts. Meanwhile, the components in the functional composition for improving bone and joint health are natural and have good biocompatibility, and have no obvious side effects, so that the application provides a kind of drug or a substitute for the treatment and prevention of bone diseases.

To accurately predict a locomotorium disease in an estimation device, method, and program.SOLUTION: An estimation device includes at least one processor. The processor functions as a learned neural network for deriving an estimation result related to bone density of a bone part from a plain radiation image acquired by executing plain radiography of a subject including the bone part. The learned neural network is learned by using, as teacher data, (i) two radiation images acquired by imaging the subject including the bone part by radioactive rays with different energy distribution, (ii) the radiation image of the subject and a bone image showing the bone part of the subject, or (iii) the radiation image of the subject and a bone density image indicating the bone density of the bone part of the subject, and information related to the bone density of the bone part of the subject.SELECTED DRAWING: Figure 3

Embodiments of the disclosure include methods and compositions related to modulation of bone using particular fibroblasts. The modulation includes reducing osteoclast activity and / or activation and / or stimulating osteoblast activity. In particular cases, bone is modulated in an individual with a bone condition, such as osteoporosis. Particular fibroblasts may be delivered to reduce inflammatory cytokine production including RANK ligand.

To provide a novel Lactobacillus paracasei strain with bone regeneration effects, and pharmaceutical and food compositions containing the same. [Solution] The present invention relates to a novel Lactobacillus paracasei L-30 and its uses, and more particularly to Lactobacillus paracasei L-30 (KCTC16035BP) which has the ability to promote the differentiation or formation of osteoblasts, the ability to suppress the differentiation or formation of osteoclasts, and the ability to promote immune activity, and which can regenerate bone, and to a pharmaceutical composition for the treatment or prevention of bone diseases containing the same.

The invention discloses a functional composition capable of improving bone and joint health, a conditioner and application. The functional composition comprises a first active component and a second active component, the first active component is prepared from elastin peptide, haematococcus pluvialis and ergothioneine; the second active component is prepared from one or more of herba houttuyniae and non-denatured type II collagen. Through scientific compatibility of all the components, the levels of glycosaminoglycan in chondrocytes and osteocalcin in osteoblasts are synergistically improved, and the protection effect on joint, cartilage and skeleton health is achieved. Meanwhile, a plurality of components in the functional composition capable of improving the health of the bones and the joints are natural in source, good in biocompatibility and free of obvious side effects, and a medicine or an alternative scheme thereof is provided for treatment and prevention of the bone diseases.

Provided herein are compounds that are useful for or methods of inhibiting β-catenin or disrupting the interaction between β-catenin and T-cell factor 4, which are useful in the treatment of diseases or health conditions, such as cancer, neurodegenerative, a metabolic disease, a cardiovascular disease, fibrosis, and a bone disease. In one aspect, the compounds have Formula 1 wherein R1 is —(CR42)mXR5; R2 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, aralkyl, heteroaralkyl, or heteroaryl; and R3 is —(CR62)nR7.

The present invention relates to a composition for inducing differentiation of cranial neural crest stem cells into perivascular cells, a method for producing perivascular cells from cranial neural crest stem cells, and a cell therapeutic agent composition for preventing or treating brain nervous system diseases using the perivascular cells or bone diseases using the cranial neural crest stem cells. The composition and method for inducing differentiation of cranial neural crest stem cells into perivascular cells according to an aspect of the present invention enable the specific production of from cranial neural crest stem cells. In addition, the perivascular cells can be used as a cell therapeutic agent for brain nervous system diseases and using the cranial neural crest stem cells can be used as a cell therapeutic agent for bone diseases.

One aspect relates to a composition for preventing or treating degenerative brain diseases comprising induced pluripotent stem cell-derived mitochondria. According to one aspect, the mitochondria derived from induced pluripotent stem cells were confirmed to exhibit excellent effects in removing reactive oxygen species and in reducing expression of inflammatory cytokines, thereby providing anti-inflammatory effects superior to those of mitochondria derived from other cells. When the mitochondria are treated to damaged nerve cells, recovery and regeneration effects can be confirmed on nerve cells, and as a result of administering the mitochondria to elderly mice, it was also confirmed that the mitochondria have an anti-aging effect. Accordingly, the pharmaceutical composition comprising induced pluripotent stem cell-derived mitochondria according to one aspect of the present invention can be applied in various fields for the prevention or treatment of degenerative brain diseases, particularly bone diseases caused by aging or beta amyloid aggregation.

The aqueous pharmaceutical formulation with improved stability comprises denosumab and a poloxamer, and preferably a histidine buffer and / or a sugar or sugar alcohol. The formulation is for use in the treatment or prevention of skeletal-related events associated with osteoporosis, reduced bone mass, multiple myeloma, solid tumor bone metastasis, giant cell tumor of bone, or hypercalcemia.

One aspect relates to a composition for preventing or treating degenerative brain diseases comprising induced pluripotent stem cell-derived mitochondria. According to one aspect, the mitochondria derived from induced pluripotent stem cells were confirmed to exhibit excellent effects in removing reactive oxygen species and in reducing expression of inflammatory cytokines, thereby providing anti-inflammatory effects superior to those of mitochondria derived from other cells. When the mitochondria are treated to damaged nerve cells, recovery and regeneration effects can be confirmed on nerve cells, and as a result of administering the mitochondria to elderly mice, it was also confirmed that the mitochondria have an anti-aging effect. Accordingly, the pharmaceutical composition comprising induced pluripotent stem cell-derived mitochondria according to one aspect of the present invention can be applied in various fields for the prevention or treatment of degenerative brain diseases, particularly bone diseases caused by aging or beta amyloid aggregation.

A Lactobacillus paracasei L-30 strain deposited under Accession Number KCTC16035BP has ability to promote osteoblast differentiation or formation, inhibiting osteoclast differentiation or formation, and enhancing immune activity, thereby enabling bone regeneration. A pharmaceutical composition including the Lactobacillus paracasei L-30 strain, a lysate thereof, a culture thereof, an extract thereof, and / or a fraction of the extract may be used for treating or preventing bone diseases.

The application discloses a functional composition, a conditioner and a use for treating or preventing bone and joint diseases. The composition of the functional composition comprises a first active component and a second active component, wherein the first active component comprises elastin peptide 1-500 mu g / mL, haematococcus pluvialis 40-20 mu g / mL, phyllanthus emblica 8-4 mu g / mL and mussel 1-500 mu g / mL in terms of concentration in the functional composition; and the second active component comprises broccoli water extract and / or boric acid substances. The application realizes the synergistic improvement of glycosaminoglycan and osteocalcin levels by scientific compounding, plays a protective role on joint, cartilage and bone health, and has natural, safe, good biocompatibility and no obvious side effects, and provides a kind of drug or a replacement scheme for bone disease treatment and prevention.

The invention relates to a liquid pharmaceutical composition comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine. Furthermore, it relates to a method of reducing the precipitation of an antibody or antigen-binding fragment thereof in a liquid pharmaceutical composition by adding methionine and cyclodextrin. Specifically. the liquid pharmaceutical composition comprises an anti-sclerostin antibody, hydroxypropyl-γ-cyclodextrin and methionine and can be used in the treatment of a bone disorder associated with at least one of the following: low bone formation, low bone density, low bone mineral content, low bone mass. low bone quality and low bone strength, and especially in the treatment of osteoporosis.Furthermore, the invention relates to a method of reducing injection site inflammation in a mammalian subject comprising administering a therapeutically effective amount of a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine.

Methods and materials for treating skeletal disorders are provided herein. For example, methods and materials for using a dual guanylate cyclase A and B activator (e.g., a polypeptide having the sequence set forth in SEQ ID NO:1) as a therapeutic agent for the treatment of skeletal disorders (e.g., achondroplasia) are provided herein.

Disclosed are methods and compositions for restoring Cyr61 in bone tissue. In certain aspects, the compositions comprise a recombinant Cyr61 carried in carbon nanotubes. The compositions may be used for various methods including restoring Cyr61 expression in bone, increasing bone density, or treating a bone disease in a patient.

The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

The invention belongs to the field of artificial intelligence, and provides a skeleton microstructure change real-time tracking decision management system, which comprises an image data access module, a dynamic structure analysis unit and an interactive decision output module, the image data access module is used for receiving skeleton three-dimensional time sequence data streams from the high-resolution microscopic imaging equipment and the clinical imaging equipment in real time; the dynamic structure analysis unit comprises a bone microstructure evolution identification module, a mechanical property prediction module and an intervention strategy generation module. Through cooperative work of the image data access module, the dynamic structure analysis unit and the interactive decision output module, full-chain closed-loop management from microstructure perception and mechanical property deduction to intelligent intervention decision is realized, and the ability of early warning and accurate intervention of skeleton diseases is significantly improved.

Aspects of the disclosure relate to compositions and methods for modulating bone growth, for example by increasing osteogenesis and / or decreasing osteoclastogenesis. The disclosure is based, in part, on recombinant adeno-associated virus (rAAV) vectors encoding microRNAs or miRNA inhibitors that inhibit endogenous miR-214-3p and / or mediate overexpression of miR-34a-5p in osteoblasts and osteoclasts. In some embodiments, compositions described by the disclosure are useful for treating certain bone diseases or disorders, such as osteoporosis.

The present invention relates to a novel therapeutic agent capable of treating muscle diseases, metabolic diseases, and bone diseases by simultaneously inhibiting the activin type II receptor and myostatin. Specifically, the invention relates to a bispecific protein comprising an anti-ActRII antibody and an anti-Myostatin antibody, and the use thereof. The simultaneous inhibition of the activin type II receptor and myostatin according to the present invention exhibits excellent effects of muscle growth and bone differentiation as well as weight loss; thus, it resolves the problem of muscle loss, which is a side effect of existing anti-obesity treatments, and can effectively improve various metabolic diseases. Therefore, the bispecific protein of the present invention can be utilized in various fields for the improvement and treatment of muscle diseases, metabolic diseases, and bone diseases.

The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.

The invention discloses a functional composition for treating or preventing bone and joint diseases, a conditioner and application. The functional composition comprises a first active component and a second active component, and according to the concentration of the functional composition, the first active component comprises 1 [mu] g / mL-500 [mu] g / mL of elastin peptide, 40 ng / mL-20 [mu] g / mL of haematococcus pluvialis, 8 ng / mL-4 [mu] g / mL of emblic leafflower fruit and 1 [mu] g / mL-500 [mu] g / mL of mussel; the second active component comprises a broccoli aqueous extract and / or boric acid substances. Through scientific compatibility, all the components synergistically improve the levels of glycosamine poly and osteocalcin, the health of joints, cartilages and bones is protected, the components are natural in source, safe, good in biocompatibility and free of obvious side effects, and a medicine or an alternative scheme thereof is provided for treatment and prevention of bone diseases.

The present invention relates to a process for preparation of compositions comprising human umbilical cord blood plasma and a designed specific culture medium to grow these cells in specific conditions.The compositions of the present invention are rich in regenerative factors derived from mesenchymal stem cells and together with other designed culture medium factors and processes, are useful in tissue regeneration processes and for preservation, conservation and expansion of mesenchymal stem cells. In fact, the present invention allows a better therapeutic option compared to traditional cell transplantation, as it can benefit from the local tissue response to the secreted molecules without the difficulties and complications associated to the engraftment of the allo- or xeno-transplanted mesenchymal stem cells.Therefore, the present invention is in the field of cell-based therapies for skeletal disorders, such as joint disorders, disorders of connective tissue, bone diseases, osteoporosis, and other damaged tissues, and for modulating the inflammatory process related to tissue regeneration as well.

The invention discloses sustained-release oral powder for treating osteoporosis and a preparation method of the sustained-release oral powder. The sustained-release oral powder comprises 2 parts of a supramolecular metal organic framework material sMOF, 0.8-1.0 part of microcrystalline cellulose and 0.1-0.2 part of magnesium stearate. Wherein the supramolecular metal organic framework material sMOF is formed by coordination self-assembly of Sr < 2 + >, Mg < 2 + >, alendronate (ALN), 1, 6-fructose diphosphate sodium salt (FDP) and casein phosphopeptides (CPP). The powder has excellent treatment effect, biocompatibility and slow release characteristic, can effectively promote osteoblast differentiation, inhibit osteoclast activity and reverse bone mineral density decline, and is suitable for treatment of bone diseases such as osteoporosis and fracture.

The present disclosure relates to a pharmaceutical composition for preventing or treating musculoskeletal disease, which has the effect of proliferating endogenous cells in bone marrow. More specifically, the pharmaceutical composition of the present disclosure can be used for the treatment of musculoskeletal disease since it proliferates endogenous cells in bone marrow and enhances the functions thereof.

The present invention relates to a pharmaceutical composition for treating or preventing bone diseases, comprising platelets and, more specifically, to a pharmaceutical composition for treating or preventing bone diseases, comprising artificial platelets having an increased concentration of any one growth factor selected from the group consisting of PDGF-AA, PDGF-BB, EGF, TGF-β, bFGF, and VEGF, thereby promoting the synthesis of chondrocytes, inhibiting inflammatory responses, and reducing the expression of extracellular matrix-degrading enzymes, thus enabling the recovery of bone and joint tissue.

The invention discloses an application of an IRF2BP2 gene as a target spot in preparation of a medicine for regulating chondrocyte differentiation and articular cartilage regeneration or repair, and relates to the technical field of biological medicines. When the regulation is to promote regeneration and repair of cartilage cells, the medicine is used for treating osteoarthritis related diseases. The invention further provides a treatment scheme for knocking down the expression of the targeted IRF2BP2 articular cavity injection virus for treating osteoarthritis and a short peptide inhibitor FOSL2-petide which can be specifically and competitively combined with IRF2BP2 so as to break the interaction of IRF2BP2-FOSL2, the activity of IRF2BP2 can be inhibited, cartilage repair can be effectively promoted, and the osteoarthritis can be treated. And a potential drug with high specificity and low off-target risk is provided for treatment of osteoarthritis. The synthesis process is simple, the targeting property is strong, the research and development cost and clinical risk are reduced, and the industrial prospect is wide. The IRF2BP2 inhibitor can inhibit osteogenesis in cartilage so as to shorten the long bone length and the body length, so that the IRF2BP2 inhibitor can also be used for treating bone diseases such as bone overgrowth or giant illness.

The present invention relates to a composition for treating musculoskeletal disorders, comprising leukocyte-rich platelet-rich plasma (LRPRP), thrombin, fibrinogen, and atelocollagen, and a preparation method therefor, wherein the composition, when administered to a patient with a musculoskeletal disorder, improves functions, alleviates pain, reduces the size of ruptured tendons, and induces structural regeneration of the tendons, and thus can be advantageously used as a pharmaceutical composition for preventing or treating musculoskeletal disorders. In addition, the composition of the present invention has an effect of reducing postoperative re-rupture of the rotator cuff after confirming rupture of the rotator cuff and performing suturing.